Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.91
NAS:KERX's Cash-to-Debt is ranked lower than
79% of the 1018 Companies
in the Global Biotechnology industry.

( Industry Median: 51.38 vs. NAS:KERX: 0.91 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:KERX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.73  Med: No Debt Max: No Debt
Current: 0.91
Equity-to-Asset 0.05
NAS:KERX's Equity-to-Asset is ranked lower than
91% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:KERX: 0.05 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:KERX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.18  Med: 0.78 Max: 0.93
Current: 0.05
-0.18
0.93
Debt-to-Equity 13.95
NAS:KERX's Debt-to-Equity is ranked lower than
98% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:KERX: 13.95 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:KERX' s Debt-to-Equity Range Over the Past 10 Years
Min: -15.07  Med: 2.12 Max: 13.95
Current: 13.95
-15.07
13.95
Debt-to-EBITDA -1.16
NAS:KERX's Debt-to-EBITDA is ranked lower than
99.99% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. NAS:KERX: -1.16 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NAS:KERX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.16  Med: -0.91 Max: -0.82
Current: -1.16
-1.16
-0.82
Piotroski F-Score: 4
Altman Z-Score: -7.06
Beneish M-Score: -3.43
WACC vs ROIC
22.63%
-852.75%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -203.11
NAS:KERX's Operating Margin % is ranked lower than
61% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -119.18 vs. NAS:KERX: -203.11 )
Ranked among companies with meaningful Operating Margin % only.
NAS:KERX' s Operating Margin % Range Over the Past 10 Years
Min: -9016.3  Med: -742.26 Max: 38.97
Current: -203.11
-9016.3
38.97
Net Margin % -323.92
NAS:KERX's Net Margin % is ranked lower than
66% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -105.77 vs. NAS:KERX: -323.92 )
Ranked among companies with meaningful Net Margin % only.
NAS:KERX' s Net Margin % Range Over the Past 10 Years
Min: -8585.51  Med: -783.89 Max: 41.62
Current: -323.92
-8585.51
41.62
ROE % -3235.09
NAS:KERX's ROE % is ranked lower than
99% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -38.72 vs. NAS:KERX: -3235.09 )
Ranked among companies with meaningful ROE % only.
NAS:KERX' s ROE % Range Over the Past 10 Years
Min: -3235.09  Med: -131.46 Max: 68.51
Current: -3235.09
-3235.09
68.51
ROA % -104.80
NAS:KERX's ROA % is ranked lower than
87% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. NAS:KERX: -104.80 )
Ranked among companies with meaningful ROA % only.
NAS:KERX' s ROA % Range Over the Past 10 Years
Min: -135.67  Med: -77.46 Max: 31.09
Current: -104.8
-135.67
31.09
ROC (Joel Greenblatt) % -973.48
NAS:KERX's ROC (Joel Greenblatt) % is ranked lower than
60% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: -411.81 vs. NAS:KERX: -973.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:KERX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -46369.35  Med: -7580 Max: 7114.49
Current: -973.48
-46369.35
7114.49
3-Year Revenue Growth Rate 52.00
NAS:KERX's 3-Year Revenue Growth Rate is ranked higher than
87% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:KERX: 52.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:KERX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -50 Max: 237.3
Current: 52
0
237.3
3-Year EBITDA Growth Rate 27.00
NAS:KERX's 3-Year EBITDA Growth Rate is ranked higher than
76% of the 704 Companies
in the Global Biotechnology industry.

( Industry Median: 1.90 vs. NAS:KERX: 27.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:KERX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -45.1  Med: 17.7 Max: 70.9
Current: 27
-45.1
70.9
3-Year EPS without NRI Growth Rate 37.90
NAS:KERX's 3-Year EPS without NRI Growth Rate is ranked higher than
85% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: -1.40 vs. NAS:KERX: 37.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:KERX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -44.7  Med: 18 Max: 60
Current: 37.9
-44.7
60
GuruFocus has detected 1 Warning Sign with Keryx Biopharmaceuticals Inc NAS:KERX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:KERX's 30-Y Financials

Financials (Next Earnings Date: 2018-03-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

KERX Guru Trades in Q4 2016

Joel Greenblatt 76,726 sh (New)
Seth Klarman 25,791,678 sh (unchged)
David Abrams 5,719,176 sh (unchged)
Chuck Royce 256,725 sh (-19.20%)
» More
Q1 2017

KERX Guru Trades in Q1 2017

Steven Cohen 100,000 sh (New)
Chuck Royce 256,725 sh (unchged)
David Abrams 5,719,176 sh (unchged)
Seth Klarman 25,791,678 sh (unchged)
Joel Greenblatt Sold Out
» More
Q2 2017

KERX Guru Trades in Q2 2017

Joel Greenblatt 55,639 sh (New)
Steven Cohen 1,552,700 sh (+1452.70%)
Chuck Royce 256,725 sh (unchged)
Seth Klarman 25,791,678 sh (unchged)
David Abrams 5,719,176 sh (unchged)
» More
Q3 2017

KERX Guru Trades in Q3 2017

David Abrams 5,719,176 sh (unchged)
Chuck Royce 256,725 sh (unchged)
Seth Klarman 25,791,678 sh (unchged)
Joel Greenblatt 36,288 sh (-34.78%)
Steven Cohen 100,000 sh (-93.56%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:KERX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2017-09-30 Reduce -34.78%$6.35 - $8.25 $ 4.80-33%36,288
Joel Greenblatt 2017-06-30 New Buy0.01%$5.55 - $7.04 $ 4.80-23%55,639
Joel Greenblatt 2017-03-31 Sold Out 0.01%$4.59 - $6.4 $ 4.80-12%0
Joel Greenblatt 2016-12-31 New Buy0.01%$4.16 - $6.41 $ 4.80-12%76,726
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:XKRX:095700, NAS:BOLD, NAS:MGNX, NAS:ADAP, NAS:PTCT, NAS:IMGN, BOM:540701, NAS:OMER, NAS:ZIOP, SZSE:002286, NAS:CTMX, NAS:ANIP, NAS:ALDR, NAS:LJPC, NAS:ACIU, NAS:ACRS, NAS:VNDA, HKSE:00775, NAS:CYTK, XMCE:PHM » details
Traded in other countries:KYX.Germany,
Headquarter Location:USA
Keryx Biopharmaceuticals Inc acquires and develops novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer.

Keryx Biopharmaceuticals acquires and develops novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx commenced operations in 1999 and has three key products in clinical trials for kidney disease and various cancers. The company acquired a renal disease-related drug candidate, Zerenex, and an approved diagnostic product, Accumin, in 2006.

Top Ranked Articles about Keryx Biopharmaceuticals Inc

Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in November 2017
U.S. FDA Approves Auryxia® (ferric citrate) Tablets as a Treatment for People with Iron Deficiency Anemia and Chronic Kidney Disease, Not on Dialysis
Keryx Biopharmaceuticals Announces Third Quarter 2017 Financial Results   
Keryx Biopharmaceuticals Moves Third Quarter 2017 Financial Results Call to Tuesday, November 7, 2017 at 8:00 a.m. ET
Keryx Biopharmaceuticals Announces Presentation of Real World Dialysis Data of Auryxia® at ASN’s 2017 Kidney Week
Keryx Biopharmaceuticals Announces Presentation of Post-Hoc Data From Phase 3 Study of Auryxia® (Ferric Citrate) in Adults With Iron Deficiency Anemia and Non-dialysis Dependent Chronic Kidney Disease
Keryx Biopharmaceuticals to Host Conference Call of Third Quarter 2017 Financial Results on Monday, November 6, 2017
Keryx Biopharmaceuticals Announces Presentations of New Data at the American Society of Nephrology Kidney Week 2017 Annual Meeting
Keryx Biopharmaceuticals Announces Changes to its Board of Directors
Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare Conferences in September 2017

Ratios

vs
industry
vs
history
PB Ratio 64.01
KERX's PB Ratio is ranked lower than
96% of the 923 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. KERX: 64.01 )
Ranked among companies with meaningful PB Ratio only.
KERX' s PB Ratio Range Over the Past 10 Years
Min: 1.85  Med: 7.86 Max: 101.33
Current: 64.01
1.85
101.33
PS Ratio 10.44
KERX's PS Ratio is ranked lower than
60% of the 706 Companies
in the Global Biotechnology industry.

( Industry Median: 11.76 vs. KERX: 10.44 )
Ranked among companies with meaningful PS Ratio only.
KERX' s PS Ratio Range Over the Past 10 Years
Min: 1.18  Med: 46.4 Max: 2228
Current: 10.44
1.18
2228
EV-to-EBIT -5.36
KERX's EV-to-EBIT is ranked lower than
99.99% of the 253 Companies
in the Global Biotechnology industry.

( Industry Median: 23.72 vs. KERX: -5.36 )
Ranked among companies with meaningful EV-to-EBIT only.
KERX' s EV-to-EBIT Range Over the Past 10 Years
Min: -29.7  Med: -5.3 Max: 54.6
Current: -5.36
-29.7
54.6
EV-to-EBITDA -5.40
KERX's EV-to-EBITDA is ranked lower than
99.99% of the 280 Companies
in the Global Biotechnology industry.

( Industry Median: 19.29 vs. KERX: -5.40 )
Ranked among companies with meaningful EV-to-EBITDA only.
KERX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -29.7  Med: -5.4 Max: 53.7
Current: -5.4
-29.7
53.7
EV-to-Revenue 11.33
KERX's EV-to-Revenue is ranked lower than
58% of the 752 Companies
in the Global Biotechnology industry.

( Industry Median: 12.83 vs. KERX: 11.33 )
Ranked among companies with meaningful EV-to-Revenue only.
KERX' s EV-to-Revenue Range Over the Past 10 Years
Min: -7.3  Med: 38.4 Max: 1705.9
Current: 11.33
-7.3
1705.9
Current Ratio 4.46
KERX's Current Ratio is ranked higher than
62% of the 1008 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. KERX: 4.46 )
Ranked among companies with meaningful Current Ratio only.
KERX' s Current Ratio Range Over the Past 10 Years
Min: 1.88  Med: 6.91 Max: 106.93
Current: 4.46
1.88
106.93
Quick Ratio 3.76
KERX's Quick Ratio is ranked higher than
60% of the 1007 Companies
in the Global Biotechnology industry.

( Industry Median: 3.83 vs. KERX: 3.76 )
Ranked among companies with meaningful Quick Ratio only.
KERX' s Quick Ratio Range Over the Past 10 Years
Min: 1.88  Med: 6.91 Max: 106.93
Current: 3.76
1.88
106.93
Days Inventory 220.80
KERX's Days Inventory is ranked lower than
66% of the 473 Companies
in the Global Biotechnology industry.

( Industry Median: 134.39 vs. KERX: 220.80 )
Ranked among companies with meaningful Days Inventory only.
KERX' s Days Inventory Range Over the Past 10 Years
Min: 220.8  Med: 1365.48 Max: 2886.82
Current: 220.8
220.8
2886.82
Days Sales Outstanding 65.20
KERX's Days Sales Outstanding is ranked lower than
54% of the 631 Companies
in the Global Biotechnology industry.

( Industry Median: 67.34 vs. KERX: 65.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
KERX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.51  Med: 28.12 Max: 98.47
Current: 65.2
0.51
98.47
Days Payable 80.12
KERX's Days Payable is ranked higher than
56% of the 434 Companies
in the Global Biotechnology industry.

( Industry Median: 57.10 vs. KERX: 80.12 )
Ranked among companies with meaningful Days Payable only.
KERX' s Days Payable Range Over the Past 10 Years
Min: 19.96  Med: 463.34 Max: 42743.3
Current: 80.12
19.96
42743.3

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.60
KERX's 3-Year Average Share Buyback Ratio is ranked higher than
64% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -13.20 vs. KERX: -8.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
KERX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -34.8  Med: -11.9 Max: -6.3
Current: -8.6
-34.8
-6.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 34.29
KERX's Price-to-Net-Current-Asset-Value is ranked lower than
93% of the 684 Companies
in the Global Biotechnology industry.

( Industry Median: 7.12 vs. KERX: 34.29 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
KERX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 7.45 Max: 51.64
Current: 34.29
0
51.64
Price-to-Tangible-Book 96.00
KERX's Price-to-Tangible-Book is ranked lower than
95% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 5.09 vs. KERX: 96.00 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
KERX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.93  Med: 6.76 Max: 147.92
Current: 96
0.93
147.92
Price-to-Median-PS-Value 0.22
KERX's Price-to-Median-PS-Value is ranked higher than
86% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. KERX: 0.22 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
KERX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.03  Med: 1.79 Max: 109.14
Current: 0.22
0.03
109.14
Earnings Yield (Greenblatt) % -18.62
KERX's Earnings Yield (Greenblatt) % is ranked lower than
65% of the 1021 Companies
in the Global Biotechnology industry.

( Industry Median: -7.65 vs. KERX: -18.62 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
KERX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -77911.5  Med: -11.6 Max: 27616.5
Current: -18.62
-77911.5
27616.5

More Statistics

Revenue (TTM) (Mil) $51.49
EPS (TTM) $ -1.50
Beta3.09
Short Percentage of Float20.79%
52-Week Range $4.47 - 8.38
Shares Outstanding (Mil)119.22

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 61 106 148 194
EPS ($) -1.30 -0.30 -0.04 0.23
EPS without NRI ($) -1.30 -0.30 -0.04 0.23
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAN
Positive CFROAN
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}